

THE SCENIC CLINICAL TRIAL FOR IPF COUGH

What is the SCENIC clinical trial for IPF cough?

SCENIC a clinical trial designed to assess the potential of a new inhaled therapy to significantly reduce cough and improve quality of life for those with idiopathic pulmonary fibrosis (IPF).

The medication is known as RVT-1601 and is an inhaled non-steroidal, anti-inflammatory drug from the US pharmaceutical company, RespiVant Sciences.

Participation in this clinical trial may help IPF patients with this often-debilitating condition and could lead to the first therapy approved for IPF patients with chronic cough.

The SCENIC trial will include 180 patients and will take place at sites in a number of different countries around the world.

What is involved for patients taking part in the trial?

If you decide to take part in this trial, you will be expected to participate for up to 28 weeks. During this time, you will take part in up to 12 study visits, of which 5 may be home visits, where a nurse will come to your house. The other 7 study visits will mean you travelling to one of the study centers.

The trial program would be as follows:

Phase 1: Screening for up to 4 weeks

Phase 2: 12 weeks 'blinded treatment' phase, when you will be given either the medication being investigated (in a dose of either 10 mg, 40mg or 80 mg) or a placebo. You will take the medication or placebo three times a day, via a hand-held silent electronic nebulizer device.

You will not know whether you have been given the medication or the placebo.

Phase 3: 12 weeks 'open label' extension period when all participants will receive the investigational medicine at a dose of 80mg, self-administered 3 times a day

Participants may continue to use approved IPF therapies (i.e. Esbriet or OFEV) during the study. However, certain medications for cough management may not be allowed.

All participants' travel and other costs incurred in order to take part in the clinical trial may be refunded.

Which hospitals will be sites for the trial?

For a list of current trial sites and recruitment status, please click on the following link:

https://clinicaltrials.gov/ct2/show/study/NCT03864328?term=RVT-1601&cond=IPF&rank=1&show_locs=Y#locn

Next steps

If you would like to be considered for this clinical trial, go to www.scenictrial.com to learn more.

Thank you!

Taleena Koch
Pulmonary Fibrosis Advocate for Patients & Families
Breathe Support Network
taleenakoch@gmail.com or breathewithpf@gmail.com
www.BreatheSupport.org



#LiveWithPF